Viral Safety and Clotting Factor Concentrates

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Thromb Haemost 1994; 72(04): 649
DOI: 10.1055/s-0038-1648933

Letter to the Editor

Schattauer GmbH Stuttgart

Yves Laurian

Hemophilia Center, Hopital Bicêtre, 94270 Kremlin-Bicetre, France Hemophilia Centers of Detroit MI 48201 and Washington DC 2007, USA

,

Jeanne M Lusher

Hemophilia Center, Hopital Bicêtre, 94270 Kremlin-Bicetre, France Hemophilia Centers of Detroit MI 48201 and Washington DC 2007, USA

,

Craig M Kessler

Hemophilia Center, Hopital Bicêtre, 94270 Kremlin-Bicetre, France Hemophilia Centers of Detroit MI 48201 and Washington DC 2007, USA

Further Information

Received 10 May 1994

Accepted 23 June 1994

Publication Date:
06 July 2018 (online)

References
1 Vermylen J, Briët E. Factor VIII preparations: need for prospective pharma-covigilance. Lancet 1993; 342: 694-695

Crossref PubMed Google Scholar
2 Mannucci PM. Modem treatment of haemophilia. From the shadows towards the light. Thromb Haemost 1993; 70: 17-23

Article in Thieme Connect PubMed Google Scholar